Janux Therapeutics (JANX) Total Liabilities (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Total Liabilities data on file, last reported at $86.7 million in Q1 2026.

• Quarterly Total Liabilities rose 126.33% year-over-year to $86.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.7 million (up 126.33% YoY) and the FY2025 annual result came in at $44.7 million, up 15.51% from the prior year.
• Total Liabilities advanced to $86.7 million in Q1 2026 per JANX's latest filing, from $44.7 million in the prior quarter.
• Across five years, Total Liabilities topped out at $86.7 million in Q1 2026 and bottomed at $12.5 million in Q1 2022.
• The 5-year median for Total Liabilities is $41.6 million (2022), against an average of $41.4 million.
• Peak annual rise in Total Liabilities reached 245.45% in 2022, while the deepest fall reached 25.38% in 2022.
• Tracing JANX's Total Liabilities over 5 years: stood at $43.3 million in 2022, then slipped by 16.67% to $36.1 million in 2023, then gained by 7.42% to $38.7 million in 2024, then advanced by 15.51% to $44.7 million in 2025, then surged by 93.75% to $86.7 million in 2026.
• Per Business Quant, the three latest JANX Total Liabilities figures stand at $86.7 million (Q1 2026), $44.7 million (Q4 2025), and $48.2 million (Q3 2025).

Peer Comparison